Research Topic

Immune Check Point Inhibitors for the Treatment of Cancers

About this Research Topic

Immune checkpoints are the immune modulatory molecules that either turn on a signal (co-stimulatory molecules) or turn off a signal. Check point molecules are categorized into two classes: (I) stimulatory check point proteins (CD27, CD28, OX40) that belong to tumor necrosis factor (TNF) receptor superfamily; ...

Immune checkpoints are the immune modulatory molecules that either turn on a signal (co-stimulatory molecules) or turn off a signal. Check point molecules are categorized into two classes: (I) stimulatory check point proteins (CD27, CD28, OX40) that belong to tumor necrosis factor (TNF) receptor superfamily; and (II) inhibitory check point proteins (PD-1, CTLA-4, LAG3) that are widely studied for tumor immunotherapy. In cancers, inhibitory check point proteins are stimulated by the pro-inflammatory cytokines (IL-6, TNF-, IFN-), and interact with the ligand of cytotoxic T-cells to suppress T cell mediate tumor cell killing. In tumor microenvironment, PD-1 and its ligand PDL-1 perform a vital role in tumor progression and survival by escaping tumor neutralizing immune surveillances. Accumulating evidence indicate that PD-1 is expressed on various immune cells, such as monocytes, B cells, T cells, dendritic cells and tumor-infiltrating lymphocytes (TILs) whereas PDL-1 is majorly found in tumor cells and antigen presenting cells (APCs). Thus, targeted inhibition of PD-1/PDL- 1 interaction will be a leading potential for T-cell mediated immune activation for cancer patients. In this regard, the first human trial with PD-L1 blocking inhibitors was initiated in 2008 for blood cancers. Until date six check point inhibitors including Nivolumab/Pembrolizumab (targeting PD-1), Atezolimuab/Durvalumab (targeting PDL- 1), Ipilimumab (targeting CTLA4) and “Nivolumab + Ipilimumab” have been FDA approved and close to a dozen human trials have been completed with more than 50 clinical trials currently under investigation. Recently, nanoparticles are being used for delivery of checkpoint targeting siRNAs and detection of circulating tumor infiltrating lymphocytes for cancer diagnosis. Therefore, immunotherapy has gained significant interest as a potential anti-cancer arsenal. We envisage the future of immune checkpoint blockers to be moving towards combination with other types of treatment such as kinase inhibitors, radiation therapy, chemotherapeutics as well as cancer vaccines and integration with imaging/therapy using nanomedicine and nanotechnology.

This Research Topic will focus on broad aspects in progress of tumor immunotherapy approaches. For example, (a) antibody based check point inhibitors, (b) check point inhibitors in combination with kinase inhibitors, chemotherapeutics, and radiotherapeutics, (c) nanomedicine for check point blockage, (d) development of small molecule for inhibiting check point cross talks as well as (e) nanomedical technologies used to integrate checkpoint inhibitors with imaging and therapy of cancers. We welcome high quality original articles, short reviews as well as full length review contributions related to the above


Keywords: Programmed cell death protein, immunotherapy of cancer, PD-1, PD-1 Antibody, PD1 - PDL1 - CTLA4, check point inhibitors, tumor immunotherapy, nanomedicine for immunotherapy, combination check point inhibitors


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Recent Articles

Loading..

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

30 November 2017 Manuscript
30 December 2017 Manuscript Extension

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

30 November 2017 Manuscript
30 December 2017 Manuscript Extension

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..

Comments

Loading..

Add a comment

Add comment
Back to top